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OutcomeAbstract Introduction: Diabetes mellitus is a chronic condition with devastating cardiovascular
complications. Earlier studies have reported a gender-based difference in major adverse cardiac
events (MACEs) after index PCI procedures. In the drug eluting stent era, more recent studies have
failed to show any differences in post-PCI outcomes between both genders. However, this ﬁnding
has never been veriﬁed in Egyptian patients with diabetes.
The aim of the study: The aim of the study was to compare the impact of female gender on short-
and long-term outcomes after elective PCI using drug-eluting stents (DES) in Egyptian diabetic
patients.
Patients and method: The study included 100 diabetic males and 100 diabetic females, all of whom
had DES deployed during elective PCI and followed up for 12 months. The clinical endpoints were
death, myocardial infarction (MI), target vessel revascularization (TVR), or target lesion revascu-
larization (TLR) at any time during 12 month follow-up period.
Results: Both diabetic females and males have a low and nearly equal incidence of adverse events
following PCI using DES.
Conclusion: When all patients had DES implanted and after adjustment of demographic and risk
factor/co morbidity proﬁles, there were no signiﬁcant differences in the short- or long-term PCI out-
comes of diabetic females treated with DES when compared to diabetic males.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Diabetes mellitus is a chronic condition with devastating car-
diovascular complications. It is estimated that the number ofpatients with diabetes, about 220 million by 2010 will rise to
350 million by 2025. The prevalence of diabetes was reported
as 13.5% in Egypt and it is closely associated with a concom-
itant rise in obesity rates.1
Earlier studies have reported a gender-based difference in
major adverse cardiac events (MACEs) after index PCI proce-
dures thought to be related to their smaller coronary vessel
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femoral access-site vascular complication.2
In the drug eluting stent era, more recent studies have failed
to show any differences in post-PCI outcomes between both
genders.3,4 However, comparative data concerning differences
in clinical outcomes after drug-eluting stent implantation in
diabetic patients according to gender are still not available
for the Egyptian population.
2. Aim of the study
The aim of the study was to compare the impact of female gen-
der on short- and long-term outcomes after elective PCI using
drug-eluting stents (DES) in Egyptian diabetic patients.3. Patients and methods
From August 2010 to January 2013, a total of 200 Egyptian
diabetic patients (100 men and 100 women) who underwent
drug-eluting stent implantation were studied prospectively.
Diabetes mellitus was deﬁned as fulﬁllment of at least one
of hemoglobin A1c >6.1%, or under treatment with anti-
diabetic agents (insulin or oral hypoglycemic agents). Our
study protocol was approved by the local Ethics Committee
and all patients provided consent for participation in the
study.
3.1. Exclusion criteria
1. Non-diabetic patients.
2. Patients treated with BMS.
3. Patients treated with primary PCI.
4. Patients with cardiogenic shock.
All patients were subjected to the following:
1. Careful history taking and thorough physical examination
2. Laboratory investigations:
Renal function tests.
Complete lipid proﬁle.
Fasting blood sugar and hemoglobin A1c.
Complete blood picture and coagulation proﬁle.
Creatinine kinase MB (CK-MB): measured at baseline and
8–12 h after procedure.
3. Resting 12 lead ECG: For assessment of cardiac rhythm
and signs of myocardial ischemia (ST segment and T
wave abnormalities and pathological Q waves.
4. Echo Doppler study: All patients were studied by trans-
thoracic echocardiography using commercially available
echocardiographic machines (Siemens), equipped with
3.5 MHz phased array transducer. M-mode echocardi-
ography was used to assess chamber dimensions and cal-
culation of the ejection fraction. Two dimensional
echocardiography was used for the assessment of the
overall left ventricular systolic function by eyeballing
and biplane Simpson’s rule. Pulsed wave Doppler was
used to measure peak mitral E velocity, peak mitral Avelocity and the E/A ratio. Continuous wave Doppler
was used for the assessment of ﬂow across cardiac valves
and the right ventricular systolic pressure.
5. Diagnostic coronary angiography: Performed via transfe-
moral approach, using Seldinger’s technique. The angio-
grams were done in all the standard views using right
and left coronary catheters.
6. Percutaneous coronary intervention (PCI): After arterial
access was obtained using standard technique, all
patients received a bolus dose of heparin to reach a tar-
get Activated Clotting Time (ACT) of >300 s. The tech-
nique done was noted, as well as all data of the stent(s)
used (manufacturer, type and length).
The success of the PCI procedure was deﬁned by angio-
graphic, procedural, and clinical criteria.5
a. Angiographic success: A successful PCI was deﬁned as
one that achieves a minimum stenosis diameter reduc-
tion to less than 20% in the presence of grade 3 TIMI
ﬂow (assessed by angiography).
b. Procedural success: A successful PCI should achieve
angiographic success without major clinical complica-
tions (e.g., death, MI, emergency coronary artery bypass
surgery) during hospitalization.
c. Clinical success: A clinically successful PCI includes ana-
tomic and procedural success with relief of signs and/or
symptoms of myocardial ischemia after the patient
recovers from the procedure. The long-term clinical suc-
cess requires that the short-term clinical success remains
durable and that the patient has persistent relief of signs
and symptoms of myocardial ischemia for more than
6 months after the procedure.
All patients were pretreated with 300 mg of both aspirin
and clopidogrel. Patients were maintained on aspirin 100 mg
daily lifelong and Clopidogrel 75 mg per day for at least
12 months. Clinical follow up comprised checking ofﬁce visits
and telephone contacts. All patients were observed for imme-
diate and late complications over a period of 12 months for:
a. Stent thrombosis: whether acute (during the PCI proce-
dure or within the subsequent 24 h), sub acute (between
1 and 30 days following PCI), or late (between 1 month
and 1 year following PCI).6
b. Cerebrovascular accidents (CVA)
c. Major adverse cardiac events (MACEs): deﬁned as a com-
posite of all-cause death, ACS and target lesion revascu-
larization (TLR), at anytime during 12 month follow-up
period. We deﬁned acute coronary syndrome among
patients with unstable angina and acute myocardial
infarction.Unstable anginawas diagnosed in the presence
of ischemic symptoms regardless of ST-T changes. Acute
myocardial infarction was deﬁned as the presence of
ischemic symptoms and a two-fold increase in CK-MB
level. TLR was deﬁned as repeat revascularization clini-
cally driven (recurrence of chest pain and new ECG
changes) by any lesion in a stented segment (P50%diam-
eter stenosis withP5 mmproximal or distal to theDES).7
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Data were statistically described in terms of mean ± standard
deviation (±SD), or frequencies (number of cases) and per-
centages when appropriate. Comparison of numerical vari-
ables between the study groups was done using Student t test
for independent samples. For comparing categorical data,
Chi square (v2) test was performed. Fisher’s exact correction
was used when the expected cell count is less than 5. P value
less than 0.05 was considered statistically signiﬁcant. Univari-
ate and multivariate Cox hazard regression analyses for
MACEs after adjustment of confounding factors (age, hyper-
tension, dyslipidemia, smoking, usage of insulin, statins,
ACE and ARBs, LV EF%, prior MI and multivessel disease)
were carried out. All statistical calculations were done using
computer programs SPSS (Statistical Package for the Social
Science; SPSS Inc., Chicago, IL, USA) version 15 for Micro-
soft Windows.4. Results
4.1. Baseline clinical characteristics
Of the 200 patients included in the study, 100 were females and
100 were males. Females were characterized by older age,
lower height, higher BMI, more frequent PAD, chronic renal
insufﬁciency, bronchial asthma and hypothyroidism, greater
presentation with stable angina and congestive heart failure,
higher fasting blood glucose and triglyceride levels, higher
usage of oral antiglycemic drugs, diuretics, beta blockers,
angiotensin receptor blockers and calcium channel blockers.
In contrast, male patients were found to have more frequent
hypertension, smoking, hyperlipidemia and family history of
CAD, more frequent previous PCI, greater presentation with
unstable angina and NSTEMI, higher fasting LDL and
HDL levels, and higher usage of insulin, statins, angiotensin
converting enzyme inhibitors and glycoprotein IIB/IIIA inhib-
itors as shown in Table 1.
4.2. Angiographic and procedural characteristics
The characteristics were left main stem lesions (3% in males vs.
4% in females, P= 1.000), proximal LAD lesions (49% in
males vs. 41% in females, P= 0.256), mid LAD lesions
(36% in males vs. 29% in females, P= 0.291),Proximal
LCX lesions (15% in males vs. 16% in females, P= 0.845),
distal LCX lesions (8% in males vs. 10% in females,
P= 0.621), proximal RCA lesions (22% in males vs. 24% in
females, P= 0.737), and mid RCA lesions (16% in males vs.
12% in females, P= 0.415). Males had more bifurcation
lesions (18% in males vs. 8% in females, P= 0.036), and
thrombus-containing lesions (9% in males vs. 4% in females,
P< 0.036).
There was a non-signiﬁcant larger number of stents/patient
in males (1.5 ± 0.45 in males vs.1.4 ± 0.25 in females,
P= 0.053) with a signiﬁcantly larger stent diameter
(3.13 ± 0.30 mm in males vs. 3.01 ± 0.32 mm in females,
P= 0.006) and a longer stent length (26.48 ± 6.49 mm in
males vs. 23.44 ± 7.14 mm in females, P= 0.001).There was
no signiﬁcant difference in post stenting TIMI grade ﬂowwhere 90% of males achieved TIMI 3 ﬂow compared to
87% of females with relief of signs and symptoms of myocar-
dial ischemia. There was no signiﬁcant difference in the proce-
dural time (52.45 ± 29.26 min vs. 49.53 ± 26.23 min, P=
0.45) and contrast volume (228.56 ± 65.34 ml vs.220.82 ±
59.42 ml, P= 0.38) between males and females as shown in
Table 2.
4.3. Cumulative incidence of clinical events during in-hospital
period
Females showed a relatively higher, but statistically insigniﬁ-
cant, incidence of early in-hospital complications, such as
post-procedural hematoma (3% in females vs. 2% in males,
p= 1.00) and acute stent thrombosis (2% in females vs. 1 in
males, p= 1.00).
The rate of in hospital myocardial infarction was higher in
males at 5%, mainly because of an increment in the rate of
non-STEMI (4%), compared with females (4% and 3%,
respectively, P= 1.00). The composite in hospital rate for
MACEs was not signiﬁcantly different between males and
females (8% versus 7%, P= 0.788).
Other clinical outcomes, including cardiac death, TLR, and
CABG, were similar between males and females as shown in
Table 3.
4.4. Cumulative incidence of clinical events during one year
follow-up
Within 12 months of the index PCI procedure, rates of
STEMI, NSTEMI, TVR, and MACE were not signiﬁcantly
different between males (2%, 1%, 7%, and 12%) and females
(3%, 1%, 7%, and 13%, respectively).
Other clinical outcomes, including cardiac death, CABG,
and stent thrombosis (including late, or very late), were similar
between males and females as shown in Table 4.
Univariate and multivariate Cox hazard regression analyses
for MACE after adjustment of confounding factors revealed
that female gender did not confer a higher risk upon MACEs
(adjusted HR was 1.3; 95% CI 0.60–2.45; p value 0.52) as
shown in Table 5.
5. Discussion
The number of people with diabetes has increased alarmingly
in the past two decades and this ﬁgure is expected to rise to
almost 350 million by 2025.1 Diabetes mellitus, whether type
1 or type 2, is a very strong risk factor for the accelerated
development of atherosclerosis characterized by small vessels,
long lesions and greater plaque burden.7–9 These ﬁndings have
been attributed to worse outcomes after PCI in diabetic
patients.10 DES have remarkably reduced the incidence of
restenosis compared with BMS in randomized trials11,12 and
several studies have found a favorable clinical outcome of
DES for patients with DM.13–15
Over the past several years, there has been an increasing
focus on obtaining sex-speciﬁc data in the cardiovascular area.
This is particularly important, given that cardiovascular dis-
ease remains the greatest cause of death in females, and unlike
males, the mortality rates do not seem to be declining in recent
years.16 However, comparative data concerning signiﬁcant dif-
Table 1 Baseline characteristics of population.
Females (n= 100) Males (n= 100) P value
Age, years 58.90 ± 9.794 57.88 ± 6.598 0.34
Height (cm) 157.23 ± 7.870 171.65 ± 7.870 0.001
Weight (kg) 86.35 ± 18.238 91.37 ± 14.81 0.03
Body surface area 1.82 ± 0.19 2.04 ± 0.18 0.001
Body mass index, kg/m2 34.49 ± 7.76 31.43 ± 4.67 0.009
Hypertension, n (%) 56 64 0.248
Systolic BP 145.60 ± 12.41 148.76 ± 10.33 0.19
Diastolic BP 89.66 ± 10.18 90.67 ± 11.26 0.50
Family history of CAD 18 20 0.719
Current smoker 3 45 0.001
Ex smoker 2 14 0.002
Hyperlipidemia, n (%) 60 62 0.772
Chronic renal insuﬃciency, n (%) 8 3 0.121
Previous stroke 3 3 1.0
Peripheral vascular disease (PVD) 8 6 0.579
Bronchial Asthma 6 3 0.306
Hypothyroidism 9 1 0.009
Previous PCI 18 22 0.480
Previous CABG 2 2 1.000
Presentation, n (%)
Stable angina 24 21 0.612
Unstable angina 44 48 0.570
Non-STEMI 22 25 0.617
Congestive heart failure 8 6 0.579
Labs
Fasting LDL, mmol/L 133.02 ± 23.58 143.15 ± 20.57 0.001
Fasting HDL, mmol/L 33.18 ± 2.7 35.41 ± 1.54 0.001
Fasting triglycerides, 174.62 ± 12.08 167 ± 10.35 0.23
Fasting glucose, mmol/L 143.42 ± 40.72 139.10 ± 44.1 0.47
Left ventricular ejection fraction, % 57.22 ± 6.47 58.12 ± 7.18 0.35
Medication, n (%)
Insulin 68 72 0.538
Oral antiglycemic 32 28 0.538
Statins 39 41 0.773
Beta-blockers 38 34 0.556
Diuretics 7 5 0.552
Calcium channel blockers 15 12 0.535
Angiotensin-converting enzyme blockers 45 49 0.571
Angiotensin receptor blockers 17 15 0.535
Glycoprotein IIB/IIIA inhibitors 5 7 0.552
BP, blood pressure; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; CAD, coronary artery disease; PVD,
peripheral vascular disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; Non-STEMI, non ST segment
elevation myocardial infarction; IIB/3A, glycoprotein IIb/IIIa inhibitors.
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tion according to gender are still not available for the Egyptian
population.
Our study found no signiﬁcant difference in the incidence
MACEs between males and females (during early in-hospital
period: 7% in females vs. 8% in males, p= 0.788 and within
one year from index PCI, 13% in females vs. 12% in males,
p= 0.831). After adjustment of confounding factors (age,
hypertension, dyslipidemia, smoking, usage of insulin, statins,
ACE and ARBs, LV EF%, prior MI and multivessel disease),
female gender did not confer a higher risk upon MACEs
(adjusted HR was 1.3; 95%, CI 0.60–2.45; p value 0.52).
Our results agree with most of the recent studies, Shrestha
et al.17 concluded that, despite all the unfavorable risk factors
clustering in females and complex coronary diseases in males,the two-year clinical outcomes after coronary stent placement
were comparable between Chinese males and females. Buja
et al. 18 concluded, in his registry of diabetic patients treated
by drug-eluting stents, that females were less represented, older
and needed more insulin compared to males who, on the other
hand, received larger stents, gender-related outcomes were
similar and female sex did not predict MACEs. A meta-analy-
sis by Stefanini et al.19 evaluated more than 5000 patients, and
the authors found that females undergoing PCI are usually
older, have more cardiovascular risk factors but a lower degree
of angiographic complexity, and at 2-year follow-up and after
controlling for baseline differences, females undergoing PCI
with DES had similar outcomes compared to male patients.
There was no difference in rates of cardiac death, myocardial
infarction, target lesion revascularization, target vessel revas-
Table 2 Angiographic and procedural characteristics.
Females (n= 100) Males (n= 100) P value
Diseased vessels (n)
One 54 51 0.671
Two 21 24 0.612
Three 18 16 0.707
Four 07 09 0.602
Distribution of lesions (n)
LM 4 3 1.000
Proximal LAD 41 49 0.256
Mid LAD 29 36 0.291
Distal LAD 07 10 0.447
Diagonal 06 12 0.138
Proximal LCX 16 15 0.845
Distal LCX 10 8 0.621
OM 6 6 1.000
Ramus Intermedius 3 5 0.721
Proximal RCA 24 22 0.737
Mid RCA 12 16 0.415
Distal RCA 11 14 0.521
PDA & PL 3 7 0.194
SVG-PDA 1 0 –
Bifurcation lesions 8 18 0.036
Thrombus containing lesions 4 9 0.036
Stents
Total stents (n) 144 172 0.52
Stents/patient (n) 1.40 ± 0.25 1.50 ± 0.45 0.053
Cypher stent 46 50 0.73
Taxus stent 34 42 0.46
Xience stent 36 40 0.719
Promus stent 28 40 0.447
Stent diameter (mm) 3.01 ± 0.32 3.13 ± 0.30 0.006
Stent length (mm) 23.44 ± 7.14 26.48 ± 6.49 0.001
Procedural time (min) 49.53 ± 26.23 52.45 ± 29.26 0.45
Contrast volume (mL) 220.82 ± 59.42 228.56 ± 65.34 0.38
Post stenting TIMI grade ﬂow
0 3 2
1 3 4
2 7 4
3 87 90
LM, left main; LAD, left anterior descending coronary artery; LCX, left circumﬂex coronary artery; OM, obtuse marginal coronary artery;
RCA, right coronary artery; PDA, posterior descending coronary artery; PL, postero lateral branch coronary artery; SVG, saphenous vein
graft.
Table 3 Cumulative incidence of clinical events during in-hospital period.
Females (n= 100) Males (n= 100) P value
Hematoma 3 2 1.000
MI 4 5 1.000
STEMI 1 1 –
Non-STEMI 3 4 1.000
Cardiac Death 1 1 –
TLR 1 1 –
CABG 0 0 –
TVR 1 1 –
MACE 7 8 0.788
Acute Stent thrombosis 2 1 1.000
STEMI, ST segment elevation myocardial infarction; Non-STEMI, non ST segment elevation myocardial infarction; TLR, target lesion
revascularization; CABG, coronary artery bypass graft; MI, myocardial infarction; TVR, target vessel revascularization; MACE, major adverse
cardiac events.
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Table 4 Cumulative incidence of clinical events during one year follow-up.
Females (n= 100) Males (n= 100) P value
MI 4 3 1.000
STEMI 3 2 1.000
Non-STEMI 1 1 –
Cardiac Death 2 2 1.000
CABG 0 0 –
TVR 7 7 1.000
MACE 13 12 0.831
Late Stent thrombosis 1 1 –
STEMI, ST segment elevation myocardial infarction; Non-STEMI, non ST segment elevation myocardial infarction; CABG, coronary artery
bypass graft; MI, myocardial infarction; TVR, target vessel revascularization; MACE, major adverse cardiac events.
Table 5 Univariate and multivariate Cox hazard regression analyses for MACE.
Unadjusted HR (95% CI) for females
versus males (Reference)
Adjusted HR (95% CI)
for females versus males
(reference)
MACE HR CI P value HR CI P value
1.21 0.54–1.91 0.88 1.3 0.60–2.45 0.52
MACE, major adverse cardiac events; HR, hazard risk; CI, conﬁdence interval.
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binary restenosis.
Furthermore, many studies have shown that acute angio-
graphic success, late restenosis, and clinical outcomes are
now similar between males and females, despite advanced
age and more co-morbidities in the latter. Funakoshi et al.20
reported no signiﬁcant gender difference in the incidence of
MACEs at a 3-year follow up period of the Japanese
CREDO-Koyato registry; the rate of all cause death and
ACS among women in that registry was 4.3% and 8.4%,
respectively. Ogita et al.7 showed no signiﬁcance difference in
the PCI outcome among men and women after elective drug-
eluting stent implantation in diabetic patients. Kralev et al.21
reported that female gender did not emerge as an independent
predictor of MACEs despite the worse baseline clinical fea-
tures seen in females. Lansky et al.22 concluded that despite
having more co morbid risk factors than males, females were
likely to have less extensive coronary artery disease by both
angiographic and intravascular ultrasound measures; however,
they found no signiﬁcant difference in MACEs at three years
between males and females.
Conversely, other investigators continue to report a higher
incidence of MACEs after PCI,23 higher mortality,24 higher
incidence rate of ACS and all cause death rate25 and higher
target vessel revascularization26 in females with diabetes melli-
tus treated with DES.
Our results and the results reported by Ogita et al., 7 Shres-
tha et al.,17 Buja et al.,18 Stefanini et al., 19 Funakoshi et al.,20
Kralev et al., 21 and Lansky et al.22 suggest that DES have lev-
eled the playing ﬁeld between diabetic males and females
undergoing PCI. The acute angiographic success and clinical
outcomes are similar between males and females, despite
advanced age and more co-morbidities in the latter. These
results are likely due to improvements in catheters and more
ﬂexible stent designs.6. Conclusion
Although baseline clinical variables differed between women
and men in this study, and women had less extensive coronary
lesions than men, both genders had similar outcomes after
drug-eluting stent implantation in this Egyptian population.
7. Limitations
Ours was a two center observational study of a small patient
cohort, and thus unknown confounding factors might have
affected the outcomes regardless of the adjusted analysis. The
number of events was relatively small leading to lack of statis-
tically signiﬁcant differences between women and men in these
outcome measures. Further, we did not investigate for differ-
ences in clinical outcome between the types of stents used.
Conﬂict of interest
None.
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